$-0.16 EPS Expected for PAVmed Inc. (PAVM); Morgan Stanley Trimmed Mgp Ingredients New (MGPI) Position

January 14, 2018 - By Marie Mckinney

Morgan Stanley decreased Mgp Ingredients Inc New (MGPI) stake by 14.54% reported in 2017Q3 SEC filing. Morgan Stanley sold 5,563 shares as Mgp Ingredients Inc New (MGPI)’s stock rose 22.02%. The Morgan Stanley holds 32,689 shares with $1.98 million value, down from 38,252 last quarter. Mgp Ingredients Inc New now has $1.26 billion valuation. The stock decreased 1.50% or $1.15 during the last trading session, reaching $75.41. About 95,290 shares traded. MGP Ingredients, Inc. (NASDAQ:MGPI) has risen 102.52% since January 14, 2017 and is uptrending. It has outperformed by 85.82% the S&P500.

Analysts expect PAVmed Inc. (NASDAQ:PAVM) to report $-0.16 EPS on February, 15.They anticipate $0.03 EPS change or 23.08% from last quarter’s $-0.13 EPS. After having $-0.14 EPS previously, PAVmed Inc.’s analysts see 14.29% EPS growth. The stock decreased 0.34% or $0.01 during the last trading session, reaching $2.96. About 5,870 shares traded. PAVmed Inc. (NASDAQ:PAVM) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

PAVmed Inc. operates as a medical device firm in the United States. The company has market cap of $43.07 million. The Company’s product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. It currently has negative earnings. The firm was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.

Among 3 analysts covering MGP Ingredients (NASDAQ:MGPI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. MGP Ingredients had 3 analyst reports since May 25, 2016 according to SRatingsIntel. The company was initiated on Wednesday, February 1 by Sidoti. The firm has “Buy” rating given on Wednesday, May 25 by Craig Hallum.

Since August 17, 2017, it had 0 buys, and 4 selling transactions for $2.27 million activity. Another trade for 934 shares valued at $53,518 was sold by Seaberg Karen.

Analysts await MGP Ingredients, Inc. (NASDAQ:MGPI) to report earnings on March, 14. They expect $0.49 EPS, up 2.08% or $0.01 from last year’s $0.48 per share. MGPI’s profit will be $8.19 million for 38.47 P/E if the $0.49 EPS becomes a reality. After $0.38 actual EPS reported by MGP Ingredients, Inc. for the previous quarter, Wall Street now forecasts 28.95% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts